Cerevel Therapeutics Holdings, Inc.
CERE
Rank in Stocks
#2810
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Share Price
$44.96
Last synced: 2024-08-01
Market Cap
$6.67B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Cerevel Therapeutics Holdings, Inc. (CERE)
Category
Healthcare
Revenue for Cerevel Therapeutics Holdings, Inc. (CERE)
Revenue in Mar 2024 TTM: $8.25M
According to Cerevel Therapeutics Holdings, Inc. latest financial reports the company's current revenue (TTM) is $8.25M. In 2022 the company made a revenue of 0.00 equal to the revenue in the year 2021 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cerevel Therapeutics Holdings, Inc. from 2012 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $8.25M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | -100.00% |
| 2015 | $2.72M | 13.14% |
| 2014 | $2.40M | -54.15% |
| 2013 | $5.24M | -2.38% |
| 2012 | $5.37M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 152,996.05% |
US
|
|
| $2.23B | 26,919.16% |
US
|
|
| $15.74B | 190,832.90% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 72,920.70% |
NL
|
